A68 COST EFFECTIVENESS OF TIGHT CONTROL FOR CROHN’S DISEASE WITH ADALIMUMAB-BASED TREATMENT: ECONOMIC EVALUATION OF CALM TRIAL FROM CANADIAN PERSPECTIVE

BACKGROUND: Tight control (TC) for Crohn’s disease (CD), using symptoms plus biomarkers (faecal calprotectin, C-reactive protein) to direct adalimumab (ADA) treatment, was associated with improved outcomes and considered cost effective (from United Kingdom setting) compared to clinical management (C...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Can Assoc Gastroenterol
Main Authors: Panaccione, R, Colombel, J, Bossuyt, P, Baert, F, Vanasek, T, Danalioglu, A, Novacek, G, Armuzzi, A, Reinisch, W, Johnson, S, Buessing, M, Neimark, E, Petersson, J, Robinson, A M, Thakkar, R B, Lee, W, Skup, M, D’Haens, G
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Posters Of Distinction
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6512606/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwz006.067
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados